You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs
|
|---|---|
| Published in |
Health Economics Review, September 2012
|
| DOI | 10.1186/2191-1991-2-16 |
| Pubmed ID | |
| Authors |
Francesc Homar, Virginia Lozano, Juan Martínez-Gómez, Itziar Oyagüez, Antonio Pareja, Antoni Payeras, Joaquín Serrano, Carmen Carratalá, Miguel Ángel Casado |
| Abstract |
The lower sales price of generic lamivudine has caused healthcare administrators to consider abolishing fixed-dose antiretroviral combinations (FDCs) that contain lamivudine and emtricitabine. The alternative is to administer the individual components of the FDCs separately, thus incorporating the new generic lamivudine medication. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 1 | 33% |
| Canada | 1 | 33% |
| United States | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 44 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 25% |
| Student > Bachelor | 6 | 14% |
| Researcher | 5 | 11% |
| Student > Doctoral Student | 4 | 9% |
| Other | 4 | 9% |
| Other | 5 | 11% |
| Unknown | 9 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 14% |
| Nursing and Health Professions | 5 | 11% |
| Agricultural and Biological Sciences | 5 | 11% |
| Economics, Econometrics and Finance | 4 | 9% |
| Other | 4 | 9% |
| Unknown | 11 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2012.
All research outputs
#13,674,872
of 22,685,926 outputs
Outputs from Health Economics Review
#194
of 421 outputs
Outputs of similar age
#94,888
of 169,031 outputs
Outputs of similar age from Health Economics Review
#3
of 6 outputs
Altmetric has tracked 22,685,926 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 421 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,031 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.